GURUFOCUS.COM » STOCK LIST » USA » NAS » Grifols SA (NAS:GRFS) » Definitions » Cash-to-Debt
Switch to:

Grifols Cash-to-Debt

: 0.06 (As of Jun. 2022)
View and export this data going back to 2011. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Grifols's cash to debt ratio for the quarter that ended in Jun. 2022 was 0.06.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Grifols couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2022.

The historical rank and industry rank for Grifols's Cash-to-Debt or its related term are showing as below:

GRFS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03   Med: 0.17   Max: No Debt
Current: 0.06

During the past 13 years, Grifols's highest Cash to Debt Ratio was No Debt. The lowest was 0.03. And the median was 0.17.

GRFS's Cash-to-Debt is ranked worse than
90.98% of 1086 companies
in the Drug Manufacturers industry
Industry Median: 1.11 vs GRFS: 0.06

Grifols Cash-to-Debt Historical Data

The historical data trend for Grifols's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cash-to-Debt
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 153.66 0.35 0.09 0.29

Grifols Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22
Cash-to-Debt Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.05 0.05 0.29 0.06

Competitive Comparison

For the Drug Manufacturers - General subindustry, Grifols's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Grifols Cash-to-Debt Distribution

For the Drug Manufacturers industry and Healthcare sector, Grifols's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Grifols's Cash-to-Debt falls into.



Grifols Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Grifols's Cash to Debt Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Grifols's Cash to Debt Ratio for the quarter that ended in Jun. 2022 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Grifols  (NAS:GRFS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Grifols Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Grifols's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Grifols Business Description

Grifols logo
Address
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's bioscience business contributed 77% of sales in 2021. Grifols also has smaller segments including diagnostics, hospital supplies, and biosupplies. Diagnostics is now roughly 15% of revenue following the Novartis and Hologic deals.

Grifols Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)